Cell-Free DNA Methylation as Blood-Based Biomarkers for Pancreatic Adenocarcinoma—A Literature Update

Stine Dam Henriksen*, Ole Thorlacius-Ussing

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

11 Citations (Scopus)
51 Downloads (Pure)

Abstract

Pancreatic adenocarcinoma has a horrible prognosis, which is partly due to difficulties in diagnosing the disease in an early stage. Additional blood-born biomarkers for pancreatic adenocarcinoma are needed. Epigenetic modifications, as changes in DNA methylation, is a fundamental part of carcinogenesis. The aim of this paper is to do an update on cell-free DNA methylation as blood-based biomarkers for pancreatic adenocarcinoma. The current literature including our studies clearly indicates that cell-free DNA methylation has the potential as blood-based diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. However, still no clinical applicable biomarker for pancreatic adenocarcinoma based on DNA methylation do exist. Further well-designed validation studies are needed.
Original languageEnglish
Article number5020008
JournalEpigenomes
Volume5
Issue number2
ISSN2075-4655
DOIs
Publication statusPublished - 2021

Keywords

  • pancreatic cancer
  • pancreatic ductal adenocarcinoma
  • epigenetic
  • DNA methylation
  • diagnostic biomarker
  • prognostic biomarker
  • cell-free DNA

Fingerprint

Dive into the research topics of 'Cell-Free DNA Methylation as Blood-Based Biomarkers for Pancreatic Adenocarcinoma—A Literature Update'. Together they form a unique fingerprint.

Cite this